Wrentham Breast Cancer Survivor and Owner of Norton Hair Salon Appears on The Balancing Act® Airing on Lifetime Television

  Wrentham Breast Cancer Survivor and Owner of Norton Hair Salon Appears on
  The Balancing Act® Airing on Lifetime Television

Balancing Act Breast Cancer Segment Airs on Lifetime Television on Oct. 14 and

Business Wire

WRENTHAM, Mass. & NORTON, Mass. -- October 7, 2013

Julie Megee, a Wrentham resident and breast cancer survivor, will appear on
The Balancing Act^® airing on Lifetime Television in October, National Breast
Cancer Awareness Month. In conjunction with the educational segment about
breast cancer, Ms. Megee is sponsoring a fundraiser for Breastcancer.org at
Perceptions Hair Studio, which she owns and operates in Norton, Mass.

Breast cancer survivor from Wrentham, Mass. and Norton, Mass. business owner
appears on The Balancin ...

Breast cancer survivor from Wrentham, Mass. and Norton, Mass. business owner
appears on The Balancing Act airing on Lifetime Television to discuss breast
cancer treatment and tamoxifen citrate, Soltamox. (Photo: Business Wire)

DARA BioSciences, Inc. (NASDAQ: DARA), a Raleigh, N.C.-based oncology
supportive care pharmaceutical company dedicated to providing health care
professionals a synergistic portfolio of medicines to help cancer patients
adhere to their therapy and manage side effects arising from their cancer
treatment, sponsored The Balancing Act^® segment. DARA has pledged to match
money raised for Breastcancer.org by Ms. Megee.

The segment on The Balancing Act^® airs Oct. 14 and 21 at 7 a.m. EDT during
Breast Cancer Awareness Month.

Ms. Megee’s breast cancer story is important because it underlies the
importance of early diagnosis and treatment options. After discovering a lump
in her breast during a self-exam in early 2013, she quickly scheduled a
doctor’s appointment, underwent a lumpectomy and radiation therapy, and is now
taking Soltamox^® (tamoxifen citrate) to prevent recurrence of the disease.
Soltamox^® is an oral liquid form of the commonly used medication tamoxifen,
until recently available in tablet form only.

“I have always had difficulty taking any type of tablet medication, so I asked
my oncologist if there was an alternative to the tamoxifen tablet because I
couldn’t imagine taking a tablet every day for at least five years,” Ms. Megee
said. Her doctor prescribed Soltamox^® (tamoxifen citrate) instead, the only
liquid formulation of tamoxifen available. DARA BioSciences markets Soltamox^®
in the United States.

As part of her fundraising effort to support Breastcancer.org, Ms. Megee and
her team at Perceptions Hair Studio will donate $5 for every new client
appointment. Breastcancer.org is a leading online resource for breast health
and breast cancer information. “I am grateful for the opportunity to support
Breastcancer.org which does so much to support women with breast cancer like
me,” Ms. Megee said. To donate and learn more, visit their fundraising page.

“We are grateful to Julie and her co-workers for supporting our efforts to
provide the most reliable, complete and up-to-date information about breast
cancer to help women and their loved ones make informed decisions for their
lives,” said Rita Lusen, vice president of corporate partnerships and
marketing of Breastcancer.org. “Thank you and congratulations to Julie, her
team, DARA and The Balancing Act^® on producing this timely educational
segment about breast cancer and cancer supportive care.”

Ms. Megee joins Nancy Peacock, MD, Tennessee Oncology medical oncologist and
breast cancer specialist at St. Thomas Midtown Hospital in Nashville, Tenn.,
and The Balancing Act^® host Danielle Knox in studio and discuss oncology
supportive care issues, including the importance of patient compliance to
tamoxifen therapy, and how Soltamox^® (tamoxifen citrate) oral solution may
help improve patient compliance. The segment also touches on side effects of
cancer treatment, including skin burns and oral mucositis caused by radiation
treatment and chemotherapy. DARA markets Gelclair^®, an oral rinse gel for
relief of oral mucositis pain, and Bionect^®, a topical treatment for skin
irritation and burns, in the US oncology/radiology markets. Dr. Peacock and
Julie also discuss the important role of patient educational resources such as

“We are pleased to partner with The Balancing Act^® to produce this
educational segment about breast cancer treatment and support, and appreciate
The Balancing Act’s commitment to breast cancer education and programming
during Breast Cancer Awareness Month” said David J. Drutz, MD, DARA's chief
executive officer and chief medical officer. “We are grateful to Dr. Peacock
and Ms. Megee for sharing their experiences on national television, so that
others may learn from their insights and knowledge.”

According to recently published National Comprehensive Cancer Network (NCCN)
Guidelines (Version 3.2013), tamoxifen is the most firmly established adjuvant
endocrine therapy for both premenopausal and postmenopausal women with
ER-positive breast cancer. Tamoxifen is usually administered as 20mg daily for
five years. The American Society of Clinical Oncology (ASCO) Clinical Practice
Guidelines published on July 8, 2013, recommends that in women at increased
risk of breast cancer age 35 or older, tamoxifen prophylaxis (20mg per day for
five years) should be discussed as an option to reduce the risk of estrogen
receptor (ER) positive breast cancer. Soltamox^® (tamoxifen citrate) oral
solution is bioequivalent to tamoxifen and is prescribed for the same
indications. Please see Soltamox^® Important Safety Information and the Black
Box Warning at the end of this press release. For additional information and a
copy of the complete Prescribing Information visit www.soltamox.com.

About DARA BioSciences

DARA BioSciences Inc. is an oncology supportive care pharmaceutical company
dedicated to providing healthcare professionals a synergistic portfolio of
medicines to help cancer patients adhere to their therapy and manage side
effects arising from their cancer treatment.

DARA holds exclusive U.S. marketing rights to Soltamox^® (tamoxifen citrate)
oral solution, the only liquid form of tamoxifen, used for the treatment and
prevention of breast cancer. Soltamox^® offers a choice to patients who prefer
or need a liquid form of tamoxifen. Gelclair^® is an alcohol-free bioadherent
oral rinse gel for rapid and effective relief of pain associated with oral
mucositis caused by chemotherapy and radiation treatment. DARA licensed the
U.S. rights to Soltamox^® from UK-based Rosemont Pharmaceuticals, Ltd., and
Gelclair^® from the Helsinn Group in Switzerland. Under an agreement with
Innocutis, DARA also markets Bionect (hyaluronic acid sodium salt, 0.2%), a
topical treatment for skin irritation and burns associated with radiation
therapy, in US oncology/radiology markets.

DARA is focused on expanding its portfolio of oncology supportive care
products in the US, via in-licensing and/or partnering of complementary
late-stage and approved products. In addition, the company wishes to identify
a strategic partner for the clinical development of KRN5500, currently in
Phase 2 for the treatment of chronic, treatment refractory, chemotherapy
induced peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a
Fast Track Drug, and DARA is seeking orphan status for the treatment of CCIPN.

About Breastcancer.org

Breastcancer.org is the #1 online resource for breast health and breast cancer
information and support, with more than 6,000 pages of expert-reviewed
information and a robust, dynamic peer support community. A nonprofit
organization, Breastcancer.org receives more than 12 million visits each year.

About The Balancing Act^® on Lifetime Television

Now in its 6th year, The Balancing Act^® continues to empower women in all
aspects of their lives. The mission at The Balancing Act^® is simple -- the
show strives to help today’s modern woman balance it all by bringing them
exceptional solutions to everyday problems. Entertaining, educational and
trusted by women, viewers can watch America’s premier morning show The
Balancing Act^® weekday mornings on Lifetime television at 7 a.m. (ET/PT).

For additional information or to view a segment visit www.thebalancingact.com.


Tamoxifen citrate is contraindicated in patients with known hypersensitivity
and also in women who require concomitant coumarin-type anticoagulant therapy
or in women with a history of deep vein thrombosis or pulmonary embolus. As
with other additive hormonal therapy (estrogens and androgens), hypercalcemia
has been reported in some breast cancer patients with bone metastases within a
few weeks of starting treatment with tamoxifen. If hypercalcemia does occur,
appropriate measures should be taken and, if severe, tamoxifen should be
discontinued. There is evidence of an increased incidence of thromboembolic
events, including deep vein thrombosis and pulmonary embolism, during
tamoxifen therapy. When tamoxifen is coadministered with chemotherapy, there
may be a further increase in the incidence of thromboembolic effects. Adverse
reactions to tamoxifen are relatively mild and rarely severe enough to require
discontinuation of treatment in breast cancer patients.


In Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for
Breast Cancer Serious and life-threatening events were associated with
tamoxifen in the risk reduction setting (women at high risk for cancer and
women with DCIS) include uterine malignancies, stroke and pulmonary embolism.
(see CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer
Incidence In High Risk Women). Health care providers should discuss the
potential benefits versus the potential risks of these serious events with
women at high risk of breast cancer and women with DCIS considering tamoxifen
to reduce their risk of developing breast cancer. The benefits of tamoxifen
outweigh its risks in women already diagnosed with breast cancer.

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit www.fda.gov/medwatch, or call 1-855-273 0468

Safe Harbor Statement

All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities Exchange Act
of 1934, as amended. Such forward-looking statements are subject to factors
that could cause actual results to differ materially for DARA from those
projected. Important factors that could cause actual results to differ
materially from the expectations described in these forward-looking statements
are set forth under the caption “Risk Factors” in DARA’s most recent Annual
Report on Form 10-K, filed with the SEC on March 28, 2013. Those factors
include risks and uncertainties relating to DARA's ability to timely
commercialize and generate revenues or profits from Bionect®, Soltamox®,
Gelclair® or other products given that DARA only recently hired its initial
sales force and DARA's lack of history as a revenue-generating company, FDA
and other regulatory risks relating to DARA's ability to market Bionect,
Soltamox, Gelclair or other products in the U.S. or elsewhere, DARA's ability
to develop and bring new products to market as anticipated, DARA's current
cash position and its need to raise additional capital in order to be able to
continue to fund its operations, the current regulatory environment in which
DARA develops and sells its products, the market acceptance of those products,
dependence on partners, successful performance under collaborative and other
commercial agreements, competition, the strength of DARA's intellectual
property and the intellectual property of others, the potential delisting of
DARA's common stock from the NASDAQ Capital Market, risks and uncertainties
relating to DARA's ability to successfully integrate Oncogenerix and other
risk factors identified in the documents DARA has filed, or will file, with
the Securities and Exchange Commission ("SEC"). Copies of DARA's filings with
the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in DARA's expectations with regard thereto or any change in
events, conditions, or circumstances on which any such statements are based.
DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.

Keywords: Balancing Act, DARA BioSciences, tamoxifen, liquid tamoxifen,
Soltamox, ductal carcinoma in situ, node-positive breast cancer, Tennessee
Oncology, St. Thomas Midtown Hospital, breast cancer, estrogen receptor
positive, liquid formulation.

Photos/Multimedia Gallery Available:



Media Contacts:
LaVoie Group
David Connolly or Samantha Stenbeck, 617-374-8800
Corporate Contact:
DARA BioSciences
Jenene Thomas, 908-938-1475
Press spacebar to pause and continue. Press esc to stop.